title: CYP17 T27C polymorphism and prostate cancer risk: a meta-analysis based on 31 studies.
abstract: OBJECTIVE
  The cytochrome P450 17α-hydroxylase (CYP17) plays a vital role in androgen biosynthesis. A T-to-C polymorphism in the 5' promoter region of CYP17 has been implicated as a risk factor for prostate cancer, but the results of individual studies are inconclusive or controversial. To derive a more precise estimation of the relationship, we performed an updated meta-analysis from 31 studies based on 27 publications.
  
  
  METHODS
  A comprehensive search was conducted to examine all the eligible studies of CYP17 polymorphism and prostate cancer risk. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association.
  
  
  RESULTS
  Overall, individuals with CC/CT genotype were not associated with prostate cancer risk (CC vs. TT: OR = 1.03, 95% CI = 0.86-1.24, P = 0.72, P heterogeneity < 0.0001; CT vs. TT: OR = 0.99, 95% CI = 0.87-1.12, P = 0.88, P heterogeneity = 0.0006). In the stratified analysis by ethnicity, there was a significantly increased risk of prostate cancer among individuals of African descent under the recessive model (OR = 1.56, 95% CI = 1.01-2.39, P = 0.04, P heterogeneity = 0.65).
  
  
  CONCLUSIONS
  This meta-analysis suggested that CYP17 polymorphism might be associated with prostate cancer risk among individuals of African descent.
authors.affiliation: Department of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
authors.forename: Bingbing
authors.initials: B
authors.lastname: Wei
authors.forename: Yunyun
authors.initials: Y
authors.lastname: Zhang
authors.forename: Bo
authors.initials: B
authors.lastname: Xi
authors.forename: Junkai
authors.initials: J
authors.lastname: Chang
authors.forename: Jinming
authors.initials: J
authors.lastname: Bai
authors.forename: Jiantang
authors.initials: J
authors.lastname: Su
keywords: CYP17; meta-analysis; prostate cancer
references.citation: Ann Intern Med. 1997 Nov 1;127(9):820-6
references.pmid: 9382404
references.citation: Cancer Res. 2000 Oct 15;60(20):5710-3
references.pmid: 11059764
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):120-6
references.pmid: 12582021
references.citation: Int J Cancer. 2000 Aug 1;87(3):434-7
references.pmid: 10897051
references.citation: Cancer Res. 2006 Nov 15;66(22):11077-83
references.pmid: 17108148
references.citation: Carcinogenesis. 1999 Sep;20(9):1727-31
references.pmid: 10469617
references.citation: Eur Urol. 1999;35(5-6):355-61
references.pmid: 10325489
references.citation: Prostate. 2005 May 15;63(3):240-51
references.pmid: 15538743
references.citation: Res Commun Mol Pathol Pharmacol. 2003;113-114:307-14
references.pmid: 15686129
references.citation: Front Biosci. 2006 Sep 01;11:2052-60
references.pmid: 16720291
references.citation: Anticancer Res. 2005 Mar-Apr;25(2B):1303-7
references.pmid: 15865082
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2237-46
references.pmid: 18006912
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):743-8
references.pmid: 11440959
references.citation: BMC Med Res Methodol. 2002 Aug 09;2:10
references.pmid: 12171604
references.citation: J Steroid Biochem Mol Biol. 1998 Aug;66(4):217-33
references.pmid: 9744519
references.citation: Int J Cancer. 2001 Nov 20;95(6):354-9
references.pmid: 11668516
references.citation: Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):243-7
references.pmid: 11895872
references.citation: Cancer. 2001 Sep 1;92(5):1130-7
references.pmid: 11571725
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):943-7
references.pmid: 11535545
references.citation: DNA Cell Biol. 2007 Feb;26(2):100-7
references.pmid: 17328668
references.citation: Pharmacogenetics. 1999 Oct;9(5):635-9
references.pmid: 10591544
references.citation: Cancer Genet Cytogenet. 2008 Sep;185(2):78-85
references.pmid: 18722876
references.citation: Prostate Cancer Prostatic Dis. 2002;5(1):28-31
references.pmid: 15195127
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1232-7
references.pmid: 12663709
references.citation: Cancer Detect Prev. 2006;30(3):262-8
references.pmid: 16859836
references.citation: Cancer Res. 1999 Jun 15;59(12):2825-8
references.pmid: 10383140
references.citation: Prostate. 2006 Dec 1;66(16):1729-43
references.pmid: 16998812
references.citation: Int J Cancer. 2001 Jun 1;92(5):683-6
references.pmid: 11340572
references.citation: Pharmacogenetics. 2002 Jun;12(4):307-12
references.pmid: 12042668
references.citation: Prostate Cancer Prostatic Dis. 2005;8(1):95-102
references.pmid: 15711606
references.citation: Am J Epidemiol. 2004 Oct 15;160(8):729-40
references.pmid: 15466495
references.citation: Urol Oncol. 2003 Jul-Aug;21(4):262-5
references.pmid: 12954495
references.citation: Prostate. 2008 Feb 15;68(3):296-305
references.pmid: 18163429
references.citation: Ann Hum Genet. 1955 Jun;19(4):251-3
references.pmid: 14388528
references.citation: DNA Cell Biol. 2007 Dec;26(12):873-8
references.pmid: 17961073
references.citation: Int J Cancer. 2003 Nov 1;107(2):271-5
references.pmid: 12949806
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3596-602
references.pmid: 17704407
references.citation: Cancer. 1994 Mar 15;73(6):1704-7
references.pmid: 8156498
references.citation: DNA Cell Biol. 2006 May;25(5):287-94
references.pmid: 16716118
references.citation: Hum Mol Genet. 1994 Oct;3(10):1873-6
references.pmid: 7849715
references.citation: Urology. 2007 Aug;70(2):217-20
references.pmid: 17826473
references.citation: Prostate. 2004 Apr 1;59(1):69-76
references.pmid: 14991867